Gilead Connecticut, Inc.

Gilead Sciences, Inc.

Genentech, Inc.

Kronos Bio, Inc.

Cgi Pharmaceuticals, Inc.

Neurogen Corporation

Genetech, Inc.

Jianjun Xu

Peter A Blomgren

Kevin S Currie

Jeffrey E Kropf

Scott A Mitchell

Seung H Lee

Zhongdong Zhao

Aaron C Schmitt

Jennifer R Lo

Douglas Gregory Stafford

Jin-Ming Xiong

Sundaramoorthi Swaminathan

Pavel E Zhichkin

Christian Gege

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Julie Farand

Antonio J M Barbosa

Honglu Zhang

Ravi Krishnamoorthy

William John Watkins

David M Armistead

Antonio J M Barbosa, Jr

Soumya Mitra

James P Harding

Jeff A Zablocki

John O Link

Hyung-Jung Pyun

Bertrand Leo Chenard

Chandrasekar Venkataramani

Scott E Lazerwith

Zheng-Yu Yang

Darryl Kato

Sheila M Zipfel

Rajagopal Bakthavatchalam

Charles A Blum

Gregory Notte

Juan A Guerrero

Jiayao Li

Zhimin Du

Adam James Schrier

Michael Sangi

Ashley Anne Katana

Kirk L Stevens

Jayaraman Chandrasekhar

Manuka Ghosh

Julie A Di Paolo

Antonio J Barbosa

Astrid Clarke

Scott Michael Capitosti

Nicholas Mai

Olaf Kinzel

David R Brittelli

Claus Kremoser

James William Darrow

William Martin Rennells

JinMing Xiong

Tony Lee

William M Rennells

Jinming Xiong

Jr Antonio J Barbosa

James W Darrow

Douglas G Stafford

Peter Blomgren

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyridines Syk inhibitors

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyridone and aza-pyridone compounds and methods of use

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R, R, R, and Rare as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Certain imidazopyrazines of Formula I and pharmaceutical compositions thereof are provided herein: Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Growing community of inventors

Madison, CT, United States of America

Jianjun Xu